Australia's national science agency has found that a "warm" COVID-19 vaccine suitable for remote locations is effective against all key variants of the virus. In a study published on Thursday, researchers from the Commonwealth Scientific and Industrial Research Organization (CSIRO) evaluated the efficacy of heat-tolerant coronavirus vaccine formulations developed by the Indian Institute of Science (IISc) and biotechnology company Mynvax. They found that the formulations triggered a strong immune response against all SARS-CoV-2 variants of concern in mice and hamsters. "Our data shows that all formulations of Mynvax tested result in antibodies capable of consistent and effective neutralization of the Alpha, Beta, Gamma and Delta SARS-CoV-2 variants of concern," S. S. Vasan, the CSIRO's COVID-19 project leader and co-author of the report, said in a media release.